A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3 Meeting Abstract

  

Authors:	Abou-Alfa, G. K.; Fan, J.; Heo, J.; Arai, Y.; Erinjeri, J. P.; Kuhl, C. K.; Lencioni, R.; Ren, Z.; Zeng, A.; Evans, B.; Cohen, G.; Kudo, M.
Abstract Title:	A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
Meeting Title:	ESMO Congress 2022
Journal Title:	Annals of Oncology
Volume:	33
Issue:	Suppl. 7
Meeting Dates:	2022 Sep 9-13
Meeting Location:	Paris, France
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2022-09-01
Start Page:	S874
Language:	English
ACCESSION:	WOS:000866211600715
DOI:	10.1016/j.annonc.2022.07.851
PROVIDER:	wos
Notes:	Meeting Abstract: 727TiP -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/202328